We only have this paper's title and publication details.
Read it at the source"Dalbavancin as a cost effective antibiotic." Infectious Diseases, 50(1), pp. 75–76
No takes yet. Share an insight, caveat, or question.
Nair et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: